Stop VTE Prophylaxis at Discharge for Most COVID-19 Patients

New data will spark debate about the role of postdischarge venous thromboembolism (VTE) prophylaxis in COVID-19 patients.

We know that COVID-19 patients should receive VTE prophylaxis while hospitalized...which typically stops at discharge.

Now data suggest rivaroxaban (Xarelto) 10 mg daily for 35 days postdischarge in COVID-19 patients with HIGH clotting and LOW bleeding risk reduces VTE...without increasing bleeding.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote